Who is sponsoring NCT02554539?

NCT02554539 is sponsored by Stanford University.

What drugs are being tested in NCT02554539?

Interventions in NCT02554539: Endometrial fluid aspiration.

What condition does NCT02554539 study?

NCT02554539 studies MicroRNA in Endometrial Fluid.

Is NCT02554539 still recruiting?

NCT02554539 is currently completed. Last updated 20 April 2018.

Last reviewed 2018-04-20 · How we verify

NCT02554539: miRNA_EF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transciptomic Modification Induced by miRNAs in Endometrial Fluid

Completed NA Last updated 20 April 2018

What this trial tests

NA trial testing Endometrial fluid aspiration in MicroRNA in Endometrial Fluid in 10 participants. Completed in 1 July 2017.

Timeline

1 July 2015

Primary endpoint
1 July 2017

1 July 2017

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	1 July 2015
Primary completion	1 July 2017
Estimated completion	1 July 2017
Sites	1 location across United States

Drugs / interventions tested

Endometrial fluid aspiration

Conditions studied

MicroRNA in Endometrial Fluid — all drugs for MicroRNA in Endometrial Fluid →

Sponsor

Stanford University

Who can join

Adults 21 to 45, female only, with MicroRNA in Endometrial Fluid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to understand the mechanism of communication between the uterine environment and the preimplantation human embryo. The investigators are interested in understanding how the in-utero environment during the window of implantation is different in normal weight and overweight/obese women and how this may impact the programming of the developing embryo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02554539 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 20 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02554539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing